Shaimaa Mosallam1, Maha H Ragaie2, Noha H Moftah2, Ahmed Hassen Elshafeey3, Aly Ahmed Abdelbary3,4. 1. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Giza, Egypt. 2. Department of Dermatology, STD's and Andrology, Faculty of Medicine, Minia University, Al-Minya, Egypt. 3. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt. 4. School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, Cairo, Egypt.
Abstract
PURPOSE: This manuscript aimed at encapsulating an antifungal terconazole (TCZ) into innovative novasomes for improving its penetration into the skin and clinically modulating its therapeutic efficacy. METHODS: Novasomes containing free fatty acid (FFA) as a penetration enhancer were formulated using ethanol injection technique based on 24 full factorial design to explore the impact of various formulation variables on novasomes characteristics regarding entrapment efficiency percent (EE%), particle size (PS), polydispersity index (PDI), and zeta potential (ZP). The optimum formulation was chosen using Design-Expert® software and utilized for further explorations. RESULTS: The chosen formulation (N15; including 100 mg lipid components and Span 80 to oleic acid in a ratio of 2:1 (w/w)) exhibited an EE% = 99.45 ± 0.78%, PS = 623.00 ± 2.97 nm, PDI = 0.40 ± 0.04, and ZP = -73.85 ± 0.64 mV. N15 showed spherical vesicles with a higher deformability index (DI) (9.62 ± 0.15 g) compared to traditional niosomal formulation (0.92 ± 0.12 g). Further, N15 showed superior inhibition of Candida albicans growth relative to TCZ suspension using XTT (2,3-bis-(2-methyloxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) reduction assay. Moreover, in vivo skin deposition tests revealed a superior TCZ deposition inside the skin from N15 in comparison to traditional niosomal formulation and TCZ suspension. Furthermore, histopathological examination for rats assured the safety of N15 for topical use. A clinical study conducted on infants suffering from napkin candidiasis proved the superiority of N15 to placebo in providing a complete cure of such fungal infections. CONCLUSION: Concisely, the obtained outcomes confirmed the pronounced efficacy of N15 to successfully treat skin fungal infections.
PURPOSE: This manuscript aimed at encapsulating an antifungal terconazole (TCZ) into innovative novasomes for improving its penetration into the skin and clinically modulating its therapeutic efficacy. METHODS: Novasomes containing free fatty acid (FFA) as a penetration enhancer were formulated using ethanol injection technique based on 24 full factorial design to explore the impact of various formulation variables on novasomes characteristics regarding entrapment efficiency percent (EE%), particle size (PS), polydispersity index (PDI), and zeta potential (ZP). The optimum formulation was chosen using Design-Expert® software and utilized for further explorations. RESULTS: The chosen formulation (N15; including 100 mg lipid components and Span 80 to oleic acid in a ratio of 2:1 (w/w)) exhibited an EE% = 99.45 ± 0.78%, PS = 623.00 ± 2.97 nm, PDI = 0.40 ± 0.04, and ZP = -73.85 ± 0.64 mV. N15 showed spherical vesicles with a higher deformability index (DI) (9.62 ± 0.15 g) compared to traditional niosomal formulation (0.92 ± 0.12 g). Further, N15 showed superior inhibition of Candida albicans growth relative to TCZ suspension using XTT (2,3-bis-(2-methyloxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) reduction assay. Moreover, in vivo skin deposition tests revealed a superior TCZ deposition inside the skin from N15 in comparison to traditional niosomal formulation and TCZ suspension. Furthermore, histopathological examination for rats assured the safety of N15 for topical use. A clinical study conducted on infants suffering from napkin candidiasis proved the superiority of N15 to placebo in providing a complete cure of such fungal infections. CONCLUSION: Concisely, the obtained outcomes confirmed the pronounced efficacy of N15 to successfully treat skin fungal infections.
Authors: Eman A Bsieso; Maha Nasr; Noha H Moftah; Omaima A Sammour; Nabaweya A Abd El Gawad Journal: Nanomedicine (Lond) Date: 2015-07-02 Impact factor: 5.307
Authors: Michael M Tunney; Gordon Ramage; Tyler R Field; Thomas F Moriarty; Douglas G Storey Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191
Authors: Iman Fatima; Akhtar Rasul; Shahid Shah; Malik Saadullah; Nayyer Islam; Ahmed Khames; Ahmad Salawi; Muhammad Masood Ahmed; Yosif Almoshari; Ghulam Abbas; Mohammed A S Abourehab; Sajid Mehmood Khan; Zunera Chauhdary; Meshal Alshamrani; Nader Ibrahim Namazi; Demiana M Naguib Journal: Molecules Date: 2022-05-04 Impact factor: 4.927
Authors: Heba M Aboud; Amal K Hussein; Abdallah Z Zayan; Tarek Saad Makram; Mona O Sarhan; Dina M El-Sharawy Journal: Pharmaceutics Date: 2022-04-16 Impact factor: 6.525
Authors: Rofida Albash; Maha H Ragaie; Mahmoud A El Hassab; Radwan El-Haggar; Wagdy M Eldehna; Sara T Al-Rashood; Shaimaa Mosallam Journal: Drug Deliv Date: 2022-12 Impact factor: 6.419
Authors: Sara M Soliman; Shaimaa Mosallam; Mohamed A Mamdouh; Mohammed Abdalla Hussein; Shady M Abd El-Halim Journal: Drug Deliv Date: 2022-12 Impact factor: 6.419
Authors: Mohammed H Elkomy; Shahira F El Menshawe; Rasha M Kharshoum; Amany M Abdeltwab; Raghda R S Hussein; Doaa S Hamad; Izzeddin Alsalahat; Heba M Aboud Journal: Drug Deliv Date: 2022-12 Impact factor: 6.819